Benutzer: Gast  Login
Mehr Felder
Einfache Suche
Titel:

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.

Dokumenttyp:
Journal Article
Autor(en):
Garz, Anne-Kathrin; Wolf, Saskia; Grath, Sonja; Gaidzik, Verena; Habringer, Stefan; Vick, Binje; Rudelius, Martina; Ziegenhain, Christoph; Herold, Sylvia; Weickert, Marie-Theresa; Smets, Martha; Peschel, Christian; Oostendorp, Robert A J; Bultmann, Sebastian; Jeremias, Irmela; Thiede, Christian; Döhner, Konstanze; Keller, Ulrich; Götze, Katharina S
Abstract:
Effectively targeting leukemia-initiating cells (LIC) in FLT3-ITD-mutated acute myeloid leukemia (AML) is crucial for cure. Tyrosine kinase inhibitors (TKI) have limited impact as single agents, failing to eradicate LIC in the bone marrow. Using primary AML samples and a patient-derived xenograft model, we investigated whether combining the FLT3-selective TKI crenolanib with the hypomethylating agent azacitidine (AZA) eliminates FLT3-ITD LIC and whether efficacy of this combination depends on co...     »
Zeitschriftentitel:
Oncotarget
Jahr:
2017
Band / Volume:
8
Heft / Issue:
65
Seitenangaben Beitrag:
108738-108759
Sprache:
eng
Volltext / DOI:
doi:10.18632/oncotarget.21877
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/29312564
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX